Yahoo Web Search

Search results

1. www.fool.com › investing › 2024/10/16Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The ...

   www.fool.com › investing › 2024/10/16

   • Cached

   1 day ago · Where Eli Lilly starts to really separate itself from Novo Nordisk is in other markets. For example, over the summer Lilly's Alzheimer's drug received approval from the FDA.

   • Better Buy: Novo Nordisk vs. Eli Lilly | The Motley Fool

     While Novo Nordisk is probably the better weight-management...

   • Eli Lilly vs Novo Nordisk: A Recent Study Suggests This ...

     Both Eli Lilly and Novo Nordisk have been generating...

2. Top stories

   • 

     The Motley Fool on MSN.com

     Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?

     16 hours ago

   • 

     The Financial Times

     Novo Nordisk, Eli Lilly and the GLP-1 economy

     6 days ago

   • The Financial Times

     Transcript: Novo Nordisk, Eli Lilly and the GLP-1 economy

     Eli Lilly and Novo Nordisk are already the biggest drug companies by market capitalisation that have ever drug companied, and there is reason to think they may be getting even bigger. And the reason, as many listeners may know, is the GLP-1 weight-loss drugs, a class of drugs that some analysts believe could grow to be $100bn.

     6 days ago

   View all

3. www.fool.com › investing › 2023/04/25Better Buy: Novo Nordisk vs. Eli Lilly | The Motley Fool

   www.fool.com › investing › 2023/04/25

   • Cached

   • The Case For Novo Nordisk
   • The Case For Eli Lilly
   • The Better Buy

   While Ozemipc is the brand name on everyone's lips when they talk about weight loss, it's only approved to control blood sugar and reduce the risk of heart attacks for patients with type 2 diabetes. Nevertheless, Ozempic sales soared 77% last year to $8.8 billion with help from off-labelweight-loss prescriptions as well as diabetes patients. Invest...

   See full list on fool.com

   Last summer, Eli Lilly turned a lot of heads with weight-management trial results from Mounjaro, a drug approved last year to treat patients with type 2 diabetes. Mounjaro works along similar lines as semaglutide, and it might be an even better weight-loss drug. After 28 weeks, patients treated with a maximum dose of Mounjaro lost 24.7 pounds on av...

   See full list on fool.com

   Wegovy is already approved to address chronic weight management, and Ozempic is a brand recognizable by most Americans. With this in mind, Novo Nordisk is probably the better stock for riding the weight-management trend. While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make El...

   See full list on fool.com

   • Author: Cory Renauer

4. www.ft.com › content › bd5fce01-0d4a-4d1e-a77bEli Lilly calls for scrutiny of rival Novo Nordisk’s deal to ...

   www.ft.com › content › bd5fce01-0d4a-4d1e-a77b

   Feb 6, 2024 · Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers...

5. Videos

   • 

     3:54

     youtube.com

     Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs

     9 Nov 2023

     5.2K views

   • 

     4:17

     youtube.com

     Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race

     10 Aug 2023

     16.9K views

   • 

     3:32

     youtube.com

     Eli Lilly, Novo Nordisk to test weight loss drugs for children

     22 Oct 2023

     1.1K views

   View all

6. www.fool.com › investing › 2024/08/03Eli Lilly vs Novo Nordisk: A Recent Study Suggests This ...

   www.fool.com › investing › 2024/08/03

   • Cached

   Aug 3, 2024 · Both Eli Lilly and Novo Nordisk have been generating terrific results due to their GLP-1 products, and there's still much more growth in the future for these companies.

   • Author: David Jagielski

7. www.nasdaq.com › articles › did-eli-lilly-just-getDid Eli Lilly Just Get a Leg Up on Novo Nordisk? - Nasdaq

   www.nasdaq.com › articles › did-eli-lilly-just-get

   • Cached

   Jul 13, 2024 · Eli Lilly vs. Novo Nordisk: Is there a clear winner? There are a couple of important themes to keep in mind when it comes to assessing investing in Eli Lilly over Novo Nordisk.

8. seekingalpha.com › article › 4681317-why-eli-lillyWhy Eli Lilly & Rival Novo Nordisk Won't Be Troubled By ...

   seekingalpha.com › article › 4681317-why-eli-lilly

   Mar 31, 2024 · Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs.

9. People also ask

   Should you buy Eli Lilly vs Novo Nordisk?

   • Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years? Novo Nordisk remains dominant in the weight loss space. Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider.

   Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opport…

   www.fool.com/investing/2024/10/16/eli-lilly-vs-novo-nordisk-which-weight-loss-stock/

   See all results for this question

   Will Eli Lilly & Novo Nordisk be the biggest pharmaceutical market ever?

   • Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg.

   Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Late…

   seekingalpha.com/article/4681317-why-eli-lilly-and-rival-novo-nordisk-wont-be-troubled-by-vikings-latest-weight-loss-data

   See all results for this question

   Should you buy Novo Nordisk to take advantage of soaring weight-management sales?

   • Before buying Novo Nordisk stock to take advantage of soaring weight-management sales, you should know that Eli Lilly (LLY -3.55%) has a weight-management program too. Some analysts think Mounjaro, a diabetes treatment from Eli Lilly, could become an even bigger weight-management drug than Novo Nordisk's.

   Better Buy: Novo Nordisk vs. Eli Lilly | The Motley Fool

   www.fool.com/investing/2023/04/25/better-buy-novo-nordisk-vs-eli-lilly/

   See all results for this question

   Does Novo Nordisk have a lead on Lilly in GLP-1 market share?

   • Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, research suggests that GLP-1 drugs have applications outside of weight loss.

   Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opport…

   www.fool.com/investing/2024/10/16/eli-lilly-vs-novo-nordisk-which-weight-loss-stock/

   See all results for this question

   Will Novo Nordisk's new diabetes drug be approved for chronic weight management?

   • Sales of Novo Nordisk's diabetes drug and weight-management drugs are soaring. Eli Lilly's popular new diabetes drug, Mounjaro, could soon earn approval to address chronic weight management. Novo Nordisk is leading the chronic weight-management space now, while Eli Lilly boasts a more diverse product lineup.

   Better Buy: Novo Nordisk vs. Eli Lilly | The Motley Fool

   www.fool.com/investing/2023/04/25/better-buy-novo-nordisk-vs-eli-lilly/

   See all results for this question

   Is Novo Nordisk a good stock to buy now?

   • While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make Eli Lilly the better overall pharmaceutical business. A more reasonable valuation makes me want to call Novo Nordisk the better buy now, but that probably isn't the best course of action.

   Better Buy: Novo Nordisk vs. Eli Lilly | The Motley Fool

   www.fool.com/investing/2023/04/25/better-buy-novo-nordisk-vs-eli-lilly/

   See all results for this question

10. www.cnbc.com › 2023/12/06 › eli-lilly-lly-vs-novoEli Lilly LLY vs. Novo Nordisk NOVO: The pros weigh in on ...

    www.cnbc.com › 2023/12/06 › eli-lilly-lly-vs-novo

    • Cached

    Dec 6, 2023 · Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks. Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around...